Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Healthcare to Receive Priority in FY2013 Draft Budget Request Guidelines
August 21, 2012
- PAFSC’s 1st Committee to Review 7 Products Including Bayer Yakuhin’s AMD Drug on Aug. 31
August 20, 2012
- Subcommittee on Refractory Diseases Prepares to Improve Medical Expenditure Subsidies: Interim Report
August 20, 2012
- PMDA Meets Targets for FY2011, but Measures Needed to Reduce Applicants’ Processing Time: MHLW’s Evaluation Council
August 20, 2012
- MHLW Designates 4 Products Including Thyroid Cancer Agent as Orphan Drugs
August 20, 2012
- US Regulation Could Delay Introduction of PBRER as ICH Standard
August 17, 2012
- 215 Preliminary Interviews Given for Regulatory Strategy Consultation in 1st Year: PMDA
August 17, 2012
- MHLW Approves Allegra Generics of 3 Companies for Listing in December
August 16, 2012
- MHLW Announces that Manufacturer’s Suggested Retail Prices of DPT-IPV Start at 6,500 Yen
August 15, 2012
- MHLW Approves Additional Indications for 8 Products Including AZ’s Symbicort
August 15, 2012
- Neo-Morgan Laboratory Developing a Variety of Organisms Using “Disparity Mutagenesis Technology”
August 14, 2012
- Drug Marketing Authorization Holders Submitted 36,641 Adverse Event Reports in FY2011: MHLW
August 14, 2012
- MHLW to Include Generic Drug Share Targets in Next 5-Year Medical Spending Optimization Plans in Response to Requests by Insurers
August 10, 2012
- MHLW Requires Revision of Package Inserts for 8 APIs including Oxaliplatin
August 9, 2012
- JPMA Calls for Maintenance and Expansion of R&D Tax Credit System at DPJ Hearings
August 9, 2012
- MHLW Study Group Takes Pass on Setting Up Relief System for Victims of Anticancer Drug Damage, Calling for Further Consideration by Government
August 8, 2012
- MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
- Talks between Health Minister, Plaintiff/Lawyer Groups Break Down on 3rd-Party Organization
August 7, 2012
- PAFSC’s First Committee Recommends Orphan Drug Designation for LAL Deficiency Treatment
August 7, 2012
- PAFSC’s First Committee Recommends Approval for Takeda’s Lotriga
August 7, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…